¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 2ÀÏÂ÷ : 2021-11-05

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 2ÀÏÂ÷ : 2021-11-05
±³À°ÀÏÀÚ : 2021-11-05
±³À°Àå¼Ò : ¿Â¶óÀÎ LIVE  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 2ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑ°¨¿°ÇÐȸ
´ã´çÀÚ : ´ëÇÑ°¨¿°ÇÐȸ
¿¬¶ôó : 02-2055-1441  
À̸ÞÀÏ : ksinfect@ksid.or.kr      
±³À°Á¾·ù : ³»°ú, ¿µ»óÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í Á¤È¸¿ø Àü¹®ÀÇ 100,000 Àü°øÀÇ 60,000 Çлý 40,000ºñȸ¿ø Àü¹®ÀÇ 120,000 Àü°øÀÇ 80,000 Çлý 50,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 07:30~07:55 Clinical research from healthcare Big-data : practice and perspective  ¼­±âÇö(½ÉÆò¿ø) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 07:55~08:20 Investigator initiated trials made easy : A to Z  ¹Ú¿Ï¹ü(¼­¿ïÀÇ´ë) 
È޽Ġ11-05 ·Ôµ¥È£ÅÚ¿ùµå 08:20~08:30 Break  () 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 08:30~09:20 Addressing unmet needs in pneumonia: moving beyond culture with molecular diagnostics  Tristan Timbrook(bioMerieux) 
È޽Ġ11-05 ·Ôµ¥È£ÅÚ¿ùµå 09:20~09:30 Break  () 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 09:30~10:00 SARS-CoV-2 infection in pregnancy: considerations for the mother and child  ±èÀǼ®(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 10:00~10:30 COVID-19 vaccination for children and adolescents  ÃÖ¿µÁØ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 10:30~11:00 How long dose immunity last after COVID-19 or Vaccination?  ³ëÁöÀ±(°í·ÁÀÇ´ë) 
È޽Ġ11-05 ·Ôµ¥È£ÅÚ¿ùµå 11:00~11:20 Break  () 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 11:20~12:10 Microbiome and Infectious diseases  ±èÁöÇö(¿¬¼¼´ë) 
È޽Ġ11-05 ·Ôµ¥È£ÅÚ¿ùµå 12:10~12:30 Break  () 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 12:30~13:20 The Past and Present of Pneumococcal Conjugate Vaccine Protection for Adults : Prevenar13  ±èÅÂÇü(¼øõÇâÀÇ´ë) 
È޽Ġ11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:20~13:30 Break  () 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:30~13:40 Association between initial viral load and outcome of patients with severe fever with thrombocytopenia  Áø¼Ö(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:40~13:50 The immunogenicity and protective efficacy of MMR vaccine among healthcare workers  ¼®Çý¸®(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 13:50~14:00 Need for a third dose of measles containing vaccine among young-aged healthcare workers in measles elimination setting  ±è¿ëÂù(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:00~14:10 Time trends in cancer incidence among people living with HIV/AIDS, 2007-2018: A nationwide population-based study  Á¤¿ì¿ë(ÀÏ»ê°ø´Üº´¿ø) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:10~14:20 Population pharmacokinetics of piperacillin-tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation  ±è¿ë±Õ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:20~14:30 Letermovir prophylaxis for cytomegalovirus in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study at a single center in Korea  ³ë´öÈñ(°¡Å縯ÀÇ´ë) 
È޽Ġ11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:30~14:40 Break  () 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:40~14:50 Äڷγª19 À¯Çà¿¡ µû¸¥ ±¹³» º´¿ø¿¡¼­ÀÇ Ç×»ýÁ¦ »ç¿ë ÆÐÅÏ º¯È­ ºÐ¼®  ±èºÀ¿µ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 14:50~15:00 The impact of a multidisciplinary antimicrobial stewardship on antimicrobial consumption and factors affecting compliance to recommendations: A quasi-experimental study  À¯Áø¼¼(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:00~15:10 »ó±ÞÁ¾ÇÕº´¿øÀÇ Ç×»ýÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ÀÇ ´Ü°èÀû È®´ë°¡ Ç×»ýÁ¦ »ç¿ë ¹× ³»¼º·ü¿¡ ¹ÌÄ¡´Â ¿µÇ⠺м®  ½Åµ¿ÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:10~15:20 Ç÷¾×³»°úº´µ¿ÀÇ Áø±Õ Æ÷ÀÚ ³óµµ °ø±â ¹è¾ç °á°ú  Á¶À縲(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:20~15:30 Risk factors of Clostridioides Difficile toxin retainments in hospitalized patients who are older than 65 years with infectious disease through CD toxin PCR screening test at the time of admission.  À̱⺴(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:30~15:40 Clinical and microbiological characteristics of, and risk factors for bloodstream infections among patients with extracorporeal membrane oxygenation  ÀÌÀºÈ­(¿¬¼¼ÀÇ´ë) 
È޽Ġ11-05 ·Ôµ¥È£ÅÚ¿ùµå 15:40~16:00 Break  () 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 16:00~16:30 Implementation of NGS into clinical diagnosis of infectious diseases  È«±âÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 16:30~17:00 Antibiotics dosing on special situations: RRT, ECMO, etc  ±è¿ë±Õ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-05 ·Ôµ¥È£ÅÚ¿ùµå 17:00~17:30 Antimicrobial stewardship in immunocompromised patients  ÀÌ»ó¿À(¿ï»êÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°¨¿°ÇÐȸ (¿Â¶óÀÎ) ICIC 2021 (5th Interscience Conference of Infection and Chemotherapy) 2ÀÏÂ÷ : 2021-11-05""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦33Â÷ Ãß°èÇмú´ëȸ : 2021-11-05
´ÙÀ½±Û (¿Â¶óÀÎ) Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ (3ÀÏÂ÷) : 2021-11-05
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
135 °æ±â Á¦59ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ¼¼¹Ì³ª : 2018-08-26 0 1,837 2018-07-28
134 ¼­¿ï Á¦8ȸ »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â¼¾ÅÍ ½ÉÆ÷Áö¾ö(ÁÖÁ¦: ÈçÈ÷ ¸¸³ª°Ô µÇ´Â ¼Ò¾Æû¼Ò³â Áúȯ) : 2018-08-26 0 715 2018-07-28
133 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Á¦9ȸ ¿¬¼¼ÀÇ´ë ¼Ò¾Æ°úÇб³½Ç, ¼Ò¾Æ¾Ë·¹¸£±âÈ£Èí±âÁúȯ ¿¬¼ö°­Á : 2018-08-26 0 395 2018-07-28
132 ¼­¿ï 2018 ´ëÇѼö¸éÇÐȸ ¿öÅ©¼¥ : 2018-08-26 0 482 2018-07-28
131 °æºÏ ´ëÇѼҾưúÇÐȸ ¼Ò¾Æû¼Ò³â°ú ¿Ü·¡¿¡¼­ Àû¿ë °¡´ÉÇÑ ÀÓ»óÁö½Ä : 2018-08-26 0 652 2018-07-28
130 °æ³² ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ 2018 Post Graduate Asthma School (2ÀÏÂ÷) : 2018-08-26 0 1,080 2018-07-28
129 ¼­¿ï Á¦5ȸ ´ëÇÑ°³¿ø³»°úÀÇ»çȸ °¨¿°º´ ¹× ¹é½Å½ÉÆ÷Áö¿ò : 2018-08-26 0 527 2018-07-28
128 ¼­¿ï Á¦15Â÷ °æ±âµµÀÇ»çȸ Çмú´ëȸ : 2018-08-26 0 1,154 2018-07-28
127 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ °í/½½°üÀý Áúȯ : 2018-08-25 0 565 2018-07-28
126 ºÎ»ê ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018 ECMO Symposium and Simulation Workshop : 2018-08-25 0 2,513 2018-07-28
125 ´ëÀü 2018³â ´ëÇÑÅëÁõÇÐȸ Áö¹æ¼øȸ ÃÊÀ½ÆÄ ¹× °æ¸·¿Ü³»½Ã°æWorkshop_ÃÊÀ½ÆÄ¿öÅ©¼ó : 2018-08-25 0 626 2018-07-28
124 ´ëÀü Ãæ³²´ëÇб³º´¿ø Ãæ³²´ëÇб³ ½Å°æ¿Ü°ú ȨĿ¹Ö ½ÉÆ÷Áö¿ò : 2018-08-25 0 902 2018-07-28
123 °æºÏ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of ASCO 2018 in Korea : 2018-08-25 0 523 2018-07-28
122 ´ëÀü ´ëÇÑ°»³â±âÇÐȸ 2018 ÇÏ°è¿öÅ©¼¥ : 2018-08-25 0 384 2018-07-28
121 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¼ö¸éÀÇÇÐ:´ÙÇÐÁ¦ Áø·áÀÇ ÀüÇü : 2018-08-25 0 797 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷